Zobrazeno 1 - 10
of 41
pro vyhledávání: '"E A, Val'dman"'
Publikováno v:
Pharmaceutical Chemistry Journal. 54:340-344
The effects of low-affinity NMDA-receptor antagonists amantadine (1-aminoadamantane hydrochloride) and hemantane [N-(2-adamantyl)hexamethyleneimine hydrochloride] on morphine-induced analgesia in C57Bl/6 mice were studied. Amantadine (10 and 20 mg/kg
Publikováno v:
Reviews on Clinical Pharmacology and Drug Therapy. 17:35-40
The effectiveness of hemantane, an original adamantane derivative, in combination with the dopamine receptor agonist piribedil on the model of acute parkinsonian syndrome induced by a single intraperitoneal injection of 30 mg/kg neurotoxicin-1, induc
Publikováno v:
Bulletin of experimental biology and medicine. 170(2)
Learned helplessness (a model of depression-like state) was developed in rats by exposure to repeated inescapable electric stimulation and evaluated by the absence of attempts to escape when it could be performed. In randomly grouped outbred white ra
Autor:
Veniamin A. Khazanov, O. V. Ardashov, E A Val'dman, Еlena Ivanova, Konstantin P. Volcho, Tat`iana Voronina, Nariman F. Salakhutdinov, I. G. Kapitsa
Publikováno v:
European Journal of Pharmacology. 815:351-363
It has been found recently that monoterpenoid (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol (Diol) demonstrates high antiparkinsonian activity in some animal models. We carried out an extended study of the antiparkinsonian activity of
Publikováno v:
Advances in Parkinson's Disease. :50-60
The efficacy of some aminoadamantane derivatives used as neurodegeneration treatments is due to their ability to block NMDA receptors. But this mechanism of pharmacological action can also produce analgesic activity. Analgesic properties of two amino
Publikováno v:
Eksperimental'naia i klinicheskaia farmakologiia. 79(10)
The influence of two aminoadamantane derivatives representing low-affinity NMDA receptor antagonists, which show antiparkinsonian-like activity both in animal models and in patients with Parkinson's disease, have been studied in vivo on mice with acu
Publikováno v:
Pharmaceutical Chemistry Journal. 47:517-520
Hemantane is a novel antiparkinsonian drug that is undergoing clinical trials. Hemantane in the dosage range 10 – 40 mg/kg demonstrated anti-inflammatory activity and decreased statistically significantly the intensity of the exudative reaction in
Publikováno v:
Advances in Parkinson's Disease. :11-17
A large body of literature supports the idea that inflammation exacerbates neurodegenerative pathology. This idea is also supported by the fact that intracerebral or intraperitoneal injection of lipopolysaccharide (LPS) induces symptoms of Parkinson
Publikováno v:
Neuroscience and Behavioral Physiology. 33:853-860
Publikováno v:
Bulletin of experimental biology and medicine. 159(3)
Hemantane demonstrated a pronounced antiparkinsonian activity in the model of hemiparkinsonian syndrome provoked in rats by unilateral intracerebral injection of 6-hydroxydopamine, which was comparable to efficacy of levodopa in decreasing the durati